CHARACTERISTICS AND OBJECTIVES

CHARACTERISTICS AND OBJECTIVES

Effects of ethylene oxide on soil microbial content and some chemical characteristics.
http://eur-lex.europa.eu/Le [...] 01:01:DE:HTML

(30) Gennari, M., Negre, M., Ambrosoli, R., (1987) Effects of ethylene oxide on soil microbial content and some chemical characteristics.
http://eur-lex.europa.eu/Le [...] 01:01:EN:HTML

Aus dem Seminar ESCORT (European Standard Characteristics of beneficials Regulatory Testing),

From the Workshop European Standard Characteristics of beneficials Regulatory Testing (Escort),

Influence of storage on sediment characteristics and drying sediment on sorption coefficients of organic contaminants.
http://eur-lex.europa.eu/Le [...] 01:01:DE:HTML

(34) Sijm, Haller and Schrap (1997) Influence of storage on sediment characteristics and drying sediment on sorption coefficients of organic contaminants.
http://eur-lex.europa.eu/Le [...] 01:01:EN:HTML

Prospective Planning of Pharmacovigilance Notice to Applicants ­ Guideline on the Summary of Product Characteristics (EC December 1999 ­ Revised Version)

ICH-V3:Prospective Planning of PharmacovigilanceNotice to Applicants ­ Guideline on the Summary of Product Characteristics (EC December 1999 ­ Revised Version)

Die OECD-Definition lautet: "structured bonds have characteristics that are designed to attract a certain type of investor and/or take advantage of particular market circumstances.
http://eur-lex.europa.eu/Le [...] 03:01:DE:HTML

The OECD adopts this definition: "Structured bonds have characteristics that are designed to attract a certain type of investor and/or take advantage of particular market circumstances.
http://eur-lex.europa.eu/Le [...] 03:01:EN:HTML

21-28) abgeleitet, der gemäß IDF-Norm 135B:1991 Milk and milk products - Precision characteristics of analytical methods - Outline of collaborative study procedure durchgeführt wurde.
http://eur-lex.europa.eu/Le [...] 01:01:DE:HTML

Milk and milk products - Precision characteristics of analytical methods - Outline of collaborative study procedure.
http://eur-lex.europa.eu/Le [...] 01:01:EN:HTML

CVMP-Arbeitsgruppe WirksamkeitTitel des Dokuments Antimicrobials for veterinary use Summary of product characteristics for antimicrobial products Ectoparasiticide guidance for sheep, cattle and goats Fluid therapy

Page 46/62Points to consider on the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products Note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labellingCVMP Efficacy Working PartyDocument title Antimicrobials for veterinary use Summary of product characteristics for antimicrobial products Ectoparasiticide guidance for sheep, cattle and goats Fluid therapy

Teil I, Zusammenfassung des Dossiers, einschließlich der Zusammenfassung der Merkmale des Arzneimittels (Summary of Product Characteristics, SPC), der Expertenberichte und der quantitativen und qualitativen Zusammensetzung des Produkts; b.
http://www.emea.europa.eu/

Part I Summary of the dossier, including the Summary of Product Characteristics (SPC), the expert reports and the quantitative and qualitative composition of the product; b.
http://www.emea.europa.eu/

From 2007 onwards the allocation of appropriations will depend on the new financial perspectives 2007-2013. The annual amounts retained for this period are purely indicative.3.3. Budgetary characteristics (add rows if necessary) :

10. The Institute shall forward annually to the budgetary authority any information relevant to the outcome of the evaluation procedures.

Kapitel 2 "Aeronautical Mobile Service", Abschnitt 2.1 "Air-ground VHF communication system characteristics" und Abschnitt 2.2 "System characteristics of the ground installations" von ICAO Anhang 10, Band III, Teil 2 (Erste Ausgabe - Juli 1995 mit Änderung Nr.
http://eur-lex.europa.eu/Le [...] 25:01:DE:HTML

Chapter 2 "Aeronautical Mobile Service", Section 2.1 "Air-ground VHF communication system characteristics" and Section 2.2 "System characteristics of the ground installations" of ICAO Annex 10, Volume III, Part 2 (First Edition - July 1995 incorporating Amendment No 80).
http://eur-lex.europa.eu/Le [...] 25:01:EN:HTML

[4] Vgl. die Definition im Oslo-Handbuch, S. 9: „A technological product innovation is the implementation/commercialisation of a product with improved performance characteristics such as to deliver objectively new or improved services to the consumer. A technological process innovation is the implementation/adoption of new or significantly improved production or delivery methods. It may involve changes in equipment, human resources, working methods or a combination of these.“ (Oslo Manual: Proposed Guidelines for Collecting and Interpreting Technological Innovation Data, 1997, OECD und Europäische Kommission, http://www.oecd.org/dataoecd/35/61/2367580.pdf).

[4] As defined in the Oslo Manual page 9: “A technological product innovation is the implementation/commercialisation of a product with improved performance characteristics such as to deliver objectively new or improved services to the consumer. A technological process innovation is the implementation/adoption of new or significantly improved production or delivery methods. It may involve changes in equipment, human resources, working methods or a combination of these.” (‘Oslo Manual: Proposed Guidelines for Collecting and Interpreting Technological Innovation Data’; 1997; OECD and European Commission, available at http://www.oecd.org/dataoecd/35/61/2367580.pdf).

Note for Guidance on Clinical Investigation of Medical Products in the Treatment of Obsessive-compulsive Disorder Addendum on acute cardiac failure to the CPMP Note for Guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure Note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia Note for Guidance on Clinical investigation of steroid contraceptives in women Revision of Note for Guidance on evaluation of new anti-bacterial medicinal products (CPMP/EWP/558/95) and Note for Guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial medicinal products

Note for Guidance on Clinical Investigation of Medical Products in the Treatment of Generalised Anxiety DisorderNote for Guidance on Clinical Investigation of Medical Productsin the Treatment of Panic DisorderNote for Guidance on Clinical Investigation of Medical Products in the Treatment of Obsessive-compulsive DisorderAddendum on acute cardiac failure to the CPMP Note for Guidance on clinical investigation of medicinal products in thetreatment of acute cardiac failureNote for guidance on the evaluation of medicinal products forthe treatment of dyslipoproteinaemiaNote for Guidance on Clinical investigation of steroid contraceptives in women Revision of Note for Guidance on evaluation of new anti-bacterial medicinal products (CPMP/EWP/558/95) and Note for Guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial medicinal products

Titel des Dokuments Note for guidance on clinical investigation of medicinal products for the treatment of diabetes mellitus Note for guidance on clinical investigation of anti-depressive agents Note for guidance on clinical investigation of medicinal products for pain treatment Position paper on new modified formulations of acetyl salicylic acid in the secondary prevention of cardiovascular events Note for guidance on clinical investigation of medicinal products for treatment of peripheral arterial occlusive disease Concept paper on the revision of the Note for guidance on evaluation of new anti-bacterial medicinal product (CPMP/EWP/558/95) and the Note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial products Points to consider on biostatistical/methodological issues arising from CPMP discussion on licensing applications:

Work progamme for 2002 CPMP Efficacy Working Party Document title Note for guidance on clinical investigation of medicinal products for the treatment of diabetes mellitus Note for guidance on clinical investigation of anti-depressive agents Note for guidance on clinical investigation of medicinal products for pain treatment Position paper on new modified formulations of acetyl salicylic acid in the secondary prevention of cardiovascular

Titel des Dokuments Note for guidance on the clinical investigation of plasma derived antithrombin products Core summary of product characteristics for plasma-derived antithrombin products Note for guidance on the clinical investigation of human normal immunoglobulin for intramuscular and subcutaneous use Core summary of product characteristics for human normal immunoglobulin for intramuscular and subcutaneous use Note for Guidance on the clinical investigation of plasma derived fibrin sealants Core summary of product characteristics for plasma derived fibrin sealants Note for guidance on the clinical investigation of von Willebrand factor Core summary of product characteristics for von Willebrand factor Note for guidance on the clinical investigation of alpha1 antitrypsin Core summary of product characteristics for alpha1 antitrypsin Core summary of product characteristics for the following specific immunoglobulins:

Document title Note for guidance on the clinical investigation of plasma derived antithrombin products Core summary of product characteristics for plasma-derived antithrombin products Note for guidance on the clinical investigation of human normal immunoglobulin for intramuscular and subcutaneous use Core summary of product characteristics for human normal immunoglobulin for intramuscular and subcutaneous use Note for Guidance on the clinical investigation of plasma derived fibrin sealants Core summary of product characteristics for plasma derived fibrin sealants Note for guidance on the clinical investigation of von Willebrand factor Core summary of product characteristics for von Willebrand factor Note for guidance on the clinical investigation of alpha1 antitrypsin Core summary of product characteristics for alpha1 antitrypsin Core summary of product characteristics for the following specific immunoglobulins:

Kapitel 2 "Aeronautical Mobile Service", Abschnitt 2.1 "Air-ground VHF communication system characteristics", Abschnitt 2.3.1 "Transmitting function" und Abschnitt 2.3.2 "Receiving function", ausgenommen Unterabschnitt 2.3.2.8 "VDL - Interference Immunity Performance", von ICAO Anhang 10, Band III, Teil 2 (Erste Ausgabe - Juli 1995 mit Änderung Nr.
http://eur-lex.europa.eu/Le [...] 25:01:DE:HTML

Chapter 2 "Aeronautical Mobile Service", Section 2.1 "Air-ground VHF communication system characteristics", Section 2.3.1 "Transmitting function" and Section 2.3.2 "Receiving function" excluding sub-section 2.3.2.8 "VDL - Interference Immunity Performance" of ICAO Annex 10, Volume III, Part 2 (First Edition - July 1995 incorporating Amendment No 80).
http://eur-lex.europa.eu/Le [...] 25:01:EN:HTML